title: Pathway to artificial pancreas systems revisited: moving downstream.
abstract: Artificial pancreas (AP) systems, a long-sought quest to replicate mechanically islet physiology that is lost in diabetes, are reaching the clinic, and the potential of automating insulin delivery is about to be realized. Significant progress has been made, and the safety and feasibility of AP systems have been demonstrated in the clinical research center and more recently in outpatient "real-world" environments. An iterative road map to AP system development has guided AP research since 2009, but progress in the field indicates that it needs updating. While it is now clear that AP systems are technically feasible, it remains much less certain that they will be widely adopted by clinicians and patients. Ultimately, the true success of AP systems will be defined by successful integration into the diabetes health care system and by the ultimate metric: improved diabetes outcomes.
authors.affiliation: JDRF, New York, NY akowalski@jdrf.org.
authors.forename: Aaron
authors.initials: A
authors.lastname: Kowalski
mesh_terms: D003362:Cost-Benefit Analysis; D003922:Diabetes Mellitus, Type 1 / Q000191:economics / Q000628:therapy*; D016883:Diabetic Ketoacidosis / Q000517:prevention & control; D005544:Forecasting; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000191:economics / Q000639:trends; D019397:Pancreas, Artificial / Q000191:economics / Q000639:trends*; D017060:Patient Satisfaction; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D007004:Hypoglycemic Agents; D007328:Insulin; D005934:Glucagon